The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Previous

Hepatitis B Drug Resistance

Back to News Homepage

Next

Idera's Hep C Drug Put on Hold

Phase III Trials Begin for Boehringer's Hepatitis C Drug

May 3, 2011

Print this page

Enrolling 1,875 patients with chronic genotype-1 Hepatitis C, Boehringer will begin three phase III trials for BI 201335, an oral protease inhibitor.

Boehringer begins late-stage hep C trial

4/27/11

Boehringer Ingelheim has begun enrolling patients in North America for a phase III trial of its chronic hepatitis C virus (HCV) candidate, which already has fast track designation from US regulators.

BI 201335 is an oral protease inhibitor and will be tested with standard-of-care in both treatment-naive and treatment -experienced patients with chronic genotype-1 HCV.

Continue reading this entire article:
http://www.inpharm.com/news/155103/boehringer-bi-201335-hepatitis-c-trial

1 Comment
Share
Share

Previous

Hepatitis B Drug Resistance

Back to News Homepage

Next

Idera's Hep C Drug Put on Hold

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.

  • larry

    no big c at 8 weeks no side affecy I still cant spell